Glomerular disease: Difference between revisions
Line 216: | Line 216: | ||
! colspan="2" rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |Sub-entity | ! colspan="2" rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |Sub-entity | ||
! rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |Causes and associations | ! rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |Causes and associations | ||
! colspan=" | ! colspan="6" rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |History and Symtoms | ||
! colspan="7" align="center" style="background:#4479BA; color: #FFFFFF;" + |Laboratory Findings | ! colspan="7" align="center" style="background:#4479BA; color: #FFFFFF;" + |Laboratory Findings | ||
! colspan="3" |Pathology | ! colspan="3" |Pathology | ||
Line 233: | Line 233: | ||
|- | |- | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |History | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |History | ||
!Systemic syptoms | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Pitting edema | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Pitting edema | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hemeturia (pre-dominantly microscopic) | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hemeturia (pre-dominantly microscopic) | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hypertension | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hypertension | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Oliguria | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Oliguria | ||
|- | |- | ||
| rowspan=" | | rowspan="11" align="center" style="background:#4479BA; color: #FFFFFF;" + |Acute Nephritic Syndromes | ||
! colspan="2" |[[Poststreptococcal glomerulonephritis|Poststreptococcal Glomerulonephritis]] | ! colspan="2" |[[Poststreptococcal glomerulonephritis|Poststreptococcal Glomerulonephritis]] | ||
|Post infectios: group A beta-hemolytic streptococcus | |Post infectios: group A beta-hemolytic streptococcus | ||
|History of prior skin or throat step infection | |History of prior skin or throat step infection | ||
| | | | ||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
Line 271: | Line 269: | ||
|Systemic immune reaction to bacterial endocarditis | |Systemic immune reaction to bacterial endocarditis | ||
|History of infective endocarditis | |History of infective endocarditis | ||
| | | | ||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
Line 291: | Line 288: | ||
! colspan="2" |[[Lupus nephritis|Lupus Nephritis]] | ! colspan="2" |[[Lupus nephritis|Lupus Nephritis]] | ||
|SLE risk factors | |SLE risk factors | ||
|History of SLE features | |||
| | | | ||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
Line 307: | Line 303: | ||
| | | | ||
| | | | ||
| | |Differs based on the disease classification | ||
| | |Differs based on the disease classification | ||
| | |Differs based on the disease classification | ||
| | |Disease presentation is different based on lupus nephritis classifications | ||
|- | |- | ||
! colspan="2" |[[Goodpasture syndrome|Antiglomerular Basement Membrane Disease]] | ! colspan="2" |[[Goodpasture syndrome|Antiglomerular Basement Membrane Disease]] | ||
Line 316: | Line 312: | ||
* Young adults | * Young adults | ||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
| | |||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
Line 344: | Line 339: | ||
* History of [[mucosal]] [[infections]] (e.g. [[gastroenteritis]]) and [[upper respiratory tract infection]] | * History of [[mucosal]] [[infections]] (e.g. [[gastroenteritis]]) and [[upper respiratory tract infection]] | ||
* 2-3 days after [[infection]] (synpharyngitic) | * 2-3 days after [[infection]] (synpharyngitic) | ||
| | |||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
| - | | - | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
Line 364: | Line 358: | ||
| | | | ||
|- | |- | ||
! rowspan=" | ! rowspan="4" |[[Vasculitis|ANCA Small-Vessel Vasculitis]] | ||
! colspan="1" |[[Granulomatosis with polyangiitis|Granulomatosis with Polyangiitis (Wegener's)]] | ! colspan="1" |[[Granulomatosis with polyangiitis|Granulomatosis with Polyangiitis (Wegener's)]] | ||
| | | | ||
| | | | ||
| rowspan="2" |Constitutional symptoms, dysnea, purpura, arthralgias, and neurologic dysfunction | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|ANCA | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
! colspan="1" |[[Microscopic polyangiitis|Microscopic Polyangiitis]] | |||
| | | | ||
| | | | ||
Line 386: | Line 398: | ||
| | | | ||
|- | |- | ||
! colspan="1" |[[ | ! colspan="1" |[[Eosinophilic granulomatosis with polyangiitis|Churg-Strauss Syndrome]] | ||
| | | | ||
| | | | ||
Line 407: | Line 418: | ||
| | | | ||
|- | |- | ||
|renal-limited vasculitis (RLV) | |||
| | | | ||
| | | | ||
Line 438: | Line 448: | ||
* [[Periorbital edema]] | * [[Periorbital edema]] | ||
* [[Hypertension]] | * [[Hypertension]] | ||
| | |||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
Line 459: | Line 468: | ||
|- | |- | ||
! colspan="2" |Mesangioproliferative Glomerulonephritis | ! colspan="2" |Mesangioproliferative Glomerulonephritis | ||
| | | | ||
| | | | ||
Line 490: | Line 498: | ||
* [[Hodgkin's lymphoma|Hodgkin lymphoma]] | * [[Hodgkin's lymphoma|Hodgkin lymphoma]] | ||
* [[Thrombosis]] (due to [[Urinary system|urinary]] loss of [[Antithrombin III|antithrombin-III]]) | * [[Thrombosis]] (due to [[Urinary system|urinary]] loss of [[Antithrombin III|antithrombin-III]]) | ||
| | |||
| + | | + | ||
| - | | - | ||
| - | | - | ||
| +/- | | +/- | ||
| + | | + | ||
| + | | + | ||
Line 521: | Line 528: | ||
| | | | ||
* Adults | * Adults | ||
| | |||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
| + | | + | ||
| + | | + | ||
Line 548: | Line 554: | ||
* [[Systemic lupus erythematosus]] | * [[Systemic lupus erythematosus]] | ||
* Drugs ([[NSAIDS]], pencilamine, [[gold]], [[captopril]]) | * Drugs ([[NSAIDS]], pencilamine, [[gold]], [[captopril]]) | ||
| | |||
| | | | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
| + | | + | ||
| + | | + | ||
Line 570: | Line 575: | ||
|- | |- | ||
! colspan="2" |[[Diabetic nephropathy|Diabetic Nephropathy]] | ! colspan="2" |[[Diabetic nephropathy|Diabetic Nephropathy]] | ||
| | | | ||
| | | | ||
Line 592: | Line 596: | ||
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + | Glomerular Deposition Diseases | ! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + | Glomerular Deposition Diseases | ||
! colspan="2" |[[Light chain nephropathy|Light Chain Deposition Disease]] | ! colspan="2" |[[Light chain nephropathy|Light Chain Deposition Disease]] | ||
| | | | ||
| | | | ||
Line 613: | Line 616: | ||
|- | |- | ||
! colspan="2" |[[Amyloidosis|Renal Amyloidosis]] | ! colspan="2" |[[Amyloidosis|Renal Amyloidosis]] | ||
| | | | ||
| | | | ||
Line 634: | Line 636: | ||
|- | |- | ||
! colspan="2" |Fibrillary-Immunotactoid Glomerulopathy | ! colspan="2" |Fibrillary-Immunotactoid Glomerulopathy | ||
| | | | ||
| | | | ||
Line 655: | Line 656: | ||
|- | |- | ||
! colspan="2" |[[Fabry's disease|Fabry's Disease]] | ! colspan="2" |[[Fabry's disease|Fabry's Disease]] | ||
| | | | ||
| | | | ||
Line 677: | Line 677: | ||
! rowspan="5" align="center" style="background:#4479BA; color: #FFFFFF;" + |Pulmonary-Renal Syndromes: | ! rowspan="5" align="center" style="background:#4479BA; color: #FFFFFF;" + |Pulmonary-Renal Syndromes: | ||
! colspan="2" |[[Goodpasture syndrome|Goodpasture's syndrome]] | ! colspan="2" |[[Goodpasture syndrome|Goodpasture's syndrome]] | ||
| | | | ||
| | | | ||
Line 701: | Line 700: | ||
* [[Necrotizing]] [[vasculitis]] (no [[granuloma]]) | * [[Necrotizing]] [[vasculitis]] (no [[granuloma]]) | ||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
| | | | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
| + | | + | ||
Line 727: | Line 725: | ||
* [[Peripheral neuropathy]] | * [[Peripheral neuropathy]] | ||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
| | | | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
Line 748: | Line 745: | ||
|- | |- | ||
! colspan="2" |[[Henoch-Schönlein purpura]] | ! colspan="2" |[[Henoch-Schönlein purpura]] | ||
| | | | ||
| | | | ||
Line 769: | Line 765: | ||
|- | |- | ||
! colspan="2" |[[Cryoglobulinemia]] | ! colspan="2" |[[Cryoglobulinemia]] | ||
| | | | ||
| | | | ||
Line 791: | Line 786: | ||
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Basement Membrane Syndrome | ! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Basement Membrane Syndrome | ||
! colspan="2" |[[Anti-glomerular basement membrane antibody|Anti-GBM Disease]] | ! colspan="2" |[[Anti-glomerular basement membrane antibody|Anti-GBM Disease]] | ||
| | | | ||
| | | | ||
Line 812: | Line 806: | ||
|- | |- | ||
! colspan="2" |[[Alport syndrome|Alport's Syndrome]] | ! colspan="2" |[[Alport syndrome|Alport's Syndrome]] | ||
| | | | ||
| | | | ||
Line 833: | Line 826: | ||
|- | |- | ||
! colspan="2" |[[Thin basement membrane disease|Thin Basement Membrane Disease]] | ! colspan="2" |[[Thin basement membrane disease|Thin Basement Membrane Disease]] | ||
| | | | ||
| | | | ||
Line 854: | Line 846: | ||
|- | |- | ||
! colspan="2" |[[Nail-patella syndrome|Nail-Patella Syndrome]] | ! colspan="2" |[[Nail-patella syndrome|Nail-Patella Syndrome]] | ||
| | | | ||
| | | | ||
Line 876: | Line 867: | ||
! rowspan="6" align="center" style="background:#4479BA; color: #FFFFFF;" + | Glomerular-Vascular Syndromes | ! rowspan="6" align="center" style="background:#4479BA; color: #FFFFFF;" + | Glomerular-Vascular Syndromes | ||
! colspan="2" |Atherosclerotic Nephropathy | ! colspan="2" |Atherosclerotic Nephropathy | ||
| | | | ||
| | | | ||
Line 897: | Line 887: | ||
|- | |- | ||
! colspan="2" |[[Hypertensive nephropathy|Hypertensive Nephrosclerosis]] | ! colspan="2" |[[Hypertensive nephropathy|Hypertensive Nephrosclerosis]] | ||
| | | | ||
| | | | ||
Line 918: | Line 907: | ||
|- | |- | ||
! colspan="2" |[[Cholesterol emboli syndrome|Cholesterol Emboli]] | ! colspan="2" |[[Cholesterol emboli syndrome|Cholesterol Emboli]] | ||
| | | | ||
| | | | ||
Line 939: | Line 927: | ||
|- | |- | ||
! colspan="2" |[[Sickle-cell disease|Sickle Cell Disease]] | ! colspan="2" |[[Sickle-cell disease|Sickle Cell Disease]] | ||
| | | | ||
| | | | ||
Line 960: | Line 947: | ||
|- | |- | ||
! colspan="2" |[[Thrombotic microangiopathies|Thrombotic Microangiopathies]] | ! colspan="2" |[[Thrombotic microangiopathies|Thrombotic Microangiopathies]] | ||
| | | | ||
| | | | ||
Line 981: | Line 967: | ||
|- | |- | ||
! colspan="2" |[[Antiphospholipid syndrome|Antiphospholipid Antibody Syndrome]] | ! colspan="2" |[[Antiphospholipid syndrome|Antiphospholipid Antibody Syndrome]] | ||
| | | | ||
| | | | ||
Line 1,008: | Line 993: | ||
* 2-3 weeks after [[infection]] | * 2-3 weeks after [[infection]] | ||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
| | | | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
Line 1,029: | Line 1,013: | ||
|- | |- | ||
! colspan="2" |[[Subacute bacterial endocarditis|Subacute Bacterial Endocarditis]] | ! colspan="2" |[[Subacute bacterial endocarditis|Subacute Bacterial Endocarditis]] | ||
| | | | ||
| | | | ||
Line 1,050: | Line 1,033: | ||
|- | |- | ||
! colspan="2" |[[Human Immunodeficiency Virus (HIV)|Human Immunodeficiency Virus]] | ! colspan="2" |[[Human Immunodeficiency Virus (HIV)|Human Immunodeficiency Virus]] | ||
| | | | ||
| | | | ||
Line 1,071: | Line 1,053: | ||
|- | |- | ||
! colspan="2" |[[Hepatitis|Hepatitis B and C]] | ! colspan="2" |[[Hepatitis|Hepatitis B and C]] | ||
| | | | ||
| | | | ||
Line 1,092: | Line 1,073: | ||
|- | |- | ||
! colspan="2" |Other Viruses | ! colspan="2" |Other Viruses | ||
| | | | ||
| | | | ||
Line 1,113: | Line 1,093: | ||
|- | |- | ||
! colspan="2" |[[Syphilis]] | ! colspan="2" |[[Syphilis]] | ||
| | | | ||
| | | | ||
Line 1,134: | Line 1,113: | ||
|- | |- | ||
! colspan="2" |[[Leprosy]] | ! colspan="2" |[[Leprosy]] | ||
| | | | ||
| | | | ||
Line 1,155: | Line 1,133: | ||
|- | |- | ||
! colspan="2" |[[Malaria]] | ! colspan="2" |[[Malaria]] | ||
| | | | ||
| | | | ||
Line 1,176: | Line 1,153: | ||
|- | |- | ||
! colspan="2" |[[Schistosomiasis]] | ! colspan="2" |[[Schistosomiasis]] | ||
| | | | ||
| | | | ||
Line 1,197: | Line 1,173: | ||
|- | |- | ||
! colspan="2" |Other [[Parasites]] | ! colspan="2" |Other [[Parasites]] | ||
| | | | ||
| | | |
Revision as of 02:34, 29 May 2018
This page contains general information about Glomerular disease. For more information on specific types, please visit the pages on nephritic syndrome, nephrotic syndrome, Fabry's disease, amyloidosis, pulmonary-renal syndromes (vasculitis), thin basement membrane disease, Alport's Syndrome, anti-GBM Disease, hypertensive nephrosclerosis, and subacute bacterial endocarditis.
Glomerular disease | |
Acute Glomerulonephritis: Micro H&E high mag; an excellent example of acute exudative glomerulonephritis. Image courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2], Syed Hassan A. Kazmi BSc, MD [3]
Overview
Glomerular disease is a condition that affects the glomerulus. It consists of different diseases with different clinical courses and treatment options. Glomerular disease can be isolated hematuria, isolated proteinuria; acute or chronic glomerulonephritis, and nephrotic or nephritic features of glomerulonephritis. The end stage of all of these diseases will be glomerulosclerosi swhich is characterized by fibrosis of the glomerulus, and end-stage renal disease.
Classification
Glomerular dieseases can be classified into several clinical and pathological syndromes as below:
Syndrome | Disease |
---|---|
Acute nephritic syndromes |
|
Nephrotic syndrome | |
Glomerular Deposition Diseases |
|
Pulmonary-Renal Syndromes: | |
Basement Membrane Syndromes | |
Glomerular-Vascular Syndromes |
|
Infectious Disease–Associated Syndromes |
Also, glomerular diseases can be classified based on their clinical and urinary pattern in to below types:
Mild nephritc:
This category include mild nephritic sediment that is associated with less than half involvement of glomeruli.
Severe nephritic:
More severe clinical features such as edema, heavy proteinuria, hypertension, and/or renal failure may occur.
Nephrotic:
This syndrome is associated with heavy proteinuria and lipiduria.
Glomerular diseases also may classified by their presentation as below:
Glomerular hematuria:
1- Isolated hematuria
2- Glomerulonephritis (nephritic syndrome)
Proteinuria:
1-Isolated non-nephrotic proteinuria
Rapidly progressive glomerulonephritis
Glomerulonephritis
Glomerulonephritis which is inflammation of the glomeruli can be classified based on pathogenic type into three subtypes:
- Immune complex glomerulonephritis: Granular deposit of immune complex.
- Infection mediated types
- Autoimmune types, eg SLE
- MPGN
- IgA nephropathy (Berger nephropathy)
- Membranous nephropathy
- Anti-GBM disease: Linear deposit
- Goodpasture syndrome (renal and lung involvement)
- Renal involvement alone
- Lung involvement alone
- ANCA associated, small vessels vasculitis: Few or no deposit
Glomerulonephritis (nephritic syndrome) also may be classified based on disease course into acute or chronic nephritic syndrome; primary vs secondary causes; or systemic vs renal limited disease. For more information about nephritic syndrome classifications click here.
Pathophysiology
Microscopic Pathology
-
Glomerulonephritis: Micro H&E med mag; an excellent example of AGN with many neutrophils
-
Acute Glomerulonephritis: Micro H&E high mag; an excellent example of acute exudative glomerulonephritis.
Glomerulonephritis Videos
Rapidly progressive glomerulonephritis
{{#ev:youtube|CqSyj4cVZPE}}
Chronic glomerulonephritis
{{#ev:youtube|eA1vYarRAWo}}
Images
-
This is a low-power photomicrograph of a saggital section of end stage chronic glomerulonephritis (GN). Note the marked thinning of the cortex (arrow).
-
This is a higher-power photomicrograph of hyalinized glomeruli (arrows) and glomeruli with thick basement membranes.
-
This is a higher-power photomicrograph of hyalinized glomeruli (1) and glomeruli with thickened basement membranes (2).
-
This is a photomicrograph of interstitial and vascular lesions in end stage renal disease.
-
This is an immunofluorescent photomicrograph of granular membranous immunofluorescence (immune complex disease). The antibody used for these studies was specific for IgG.
-
This is an electron micrograph of subepithelial granular electron dense deposits (arrows) which correspond to the granular immunofluorescence seen in the previous image.
-
This is a photomicrograph of a glomerulus from another case with acute poststreptococcal glomerulonephritis. In this case the immune complex glomerular disease is ongoing with necrosis and accumulation of neutrophils in the glomerulus.
-
This immunofluorescent photomicrograph of a glomerulus from a case of acute poststreptococcal glomerulonephritis shows a granular immunofluorescence pattern consistent with immune complex disease. The primary antibody used for this staining was specific for IgG; however antibodies for complement would show a similar pattern.
-
This electron micrograph demonstrates scattered subepithelial dense deposits (arrows) and a polymorphonuclear leukocyte in the lumen.
-
For comparison this is an immunofluorescent photomicrograph of a glomerulus from a patient with Goodpasture's syndrome. The linear (arrows) immunofluorescence is characteristic of Goodpasture's syndrome.
Images:
Differential Diagnosis
Glomerulonephritis may be proliferative or non-proliferative and may be associated with nephrotic or nephritic features. The various types of glomerulonephritides should be differentiated from each other based on associations, presence of pitting edema, hemeturia, hypertension, hemoptysis, oliguria, peri-orbital edema, hyperlipidemia, type of antibodies, light and electron microscopic features. The following table differentiates between various types of glomerulonephritides:[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24]
Glomerular diseases | Sub-entity | Causes and associations | History and Symtoms | Laboratory Findings | Pathology | Comments | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hyperlipidemia and hypercholesterolemia | Nephrotic features | Nephritic features | Antibodies | ANCA | Anti-glomerular basement membrane antibody (Anti-GBM antibody) | Immune complex formation | Light microscope | Electron microscope | Immunoflourescence pattern | |||||||||||
History | Systemic syptoms | Pitting edema | Hemeturia (pre-dominantly microscopic) | Hypertension | Oliguria | |||||||||||||||
Acute Nephritic Syndromes | Poststreptococcal Glomerulonephritis | Post infectios: group A beta-hemolytic streptococcus | History of prior skin or throat step infection | +/- | +/- | +/- | +/- | +/- | +/- | +/- |
|
|
Pathologic involvement correlates with the clinical findings | |||||||
Subacute Bacterial Endocarditis | Systemic immune reaction to bacterial endocarditis | History of infective endocarditis | +/- | +/- | +/- | +/- | +/- | +/- | +/- | |||||||||||
Lupus Nephritis | SLE risk factors | History of SLE features | +/- | +/- | +/- | +/- | +/- | +/- | +/- | anti-C1q antibodies
anti-dsDNA |
Differs based on the disease classification | Differs based on the disease classification | Differs based on the disease classification | Disease presentation is different based on lupus nephritis classifications | ||||||
Antiglomerular Basement Membrane Disease |
|
+/- | + | + | + | + | - | + | - | + | + |
|
+ (Linear) | |||||||
IgA Nephropathy |
|
+/- | + | + | + | - | - | + | - | - | + |
|
|
- | ||||||
ANCA Small-Vessel Vasculitis | Granulomatosis with Polyangiitis (Wegener's) | Constitutional symptoms, dysnea, purpura, arthralgias, and neurologic dysfunction | ANCA | |||||||||||||||||
Microscopic Polyangiitis | ||||||||||||||||||||
Churg-Strauss Syndrome | ||||||||||||||||||||
renal-limited vasculitis (RLV) | ||||||||||||||||||||
Membranoproliferative Glomerulonephritis |
|
+/- | + | + | + | - | + | - | - | - | + |
|
+ (Granular) | |||||||
Mesangioproliferative Glomerulonephritis | ||||||||||||||||||||
Nephrotic Syndrome | Minimal Change Disease |
|
|
+ | - | - | +/- | + | + | - | - | - | - |
|
|
- | ||||
Focal Segmental Glomerulosclerosis |
|
|
+ | - | - | +/- | + | + | - | - | - | - |
|
|
- | |||||
Membranous Glomerulonephritis |
|
+ | - | - | +/- | + | + | - | - | - | + |
|
- | |||||||
Diabetic Nephropathy | ||||||||||||||||||||
Glomerular Deposition Diseases | Light Chain Deposition Disease | |||||||||||||||||||
Renal Amyloidosis | ||||||||||||||||||||
Fibrillary-Immunotactoid Glomerulopathy | ||||||||||||||||||||
Fabry's Disease | ||||||||||||||||||||
Pulmonary-Renal Syndromes: | Goodpasture's syndrome | |||||||||||||||||||
Microscopic polyangiitis | +/- | + | + | + | + | - | + |
+ (P-ANCA) |
- | - | - (pauci-immune) | - | ||||||||
Churg-Strauss vasculitis | +/- | + | + | + | + | - | + |
+ (C-ANCA) |
- | - | - (pauci-immune) | - | ||||||||
Henoch-Schönlein purpura | ||||||||||||||||||||
Cryoglobulinemia | ||||||||||||||||||||
Basement Membrane Syndrome | Anti-GBM Disease | |||||||||||||||||||
Alport's Syndrome | ||||||||||||||||||||
Thin Basement Membrane Disease | ||||||||||||||||||||
Nail-Patella Syndrome | ||||||||||||||||||||
Glomerular-Vascular Syndromes | Atherosclerotic Nephropathy | |||||||||||||||||||
Hypertensive Nephrosclerosis | ||||||||||||||||||||
Cholesterol Emboli | ||||||||||||||||||||
Sickle Cell Disease | ||||||||||||||||||||
Thrombotic Microangiopathies | ||||||||||||||||||||
Antiphospholipid Antibody Syndrome | ||||||||||||||||||||
Infectious Disease–Associated Syndromes | Post-Streptococcal Glomerulonephritis |
|
+/- | + | + | + | + | - | + | - | - | + |
|
+ (Granular) | ||||||
Subacute Bacterial Endocarditis | ||||||||||||||||||||
Human Immunodeficiency Virus | ||||||||||||||||||||
Hepatitis B and C | ||||||||||||||||||||
Other Viruses | ||||||||||||||||||||
Syphilis | ||||||||||||||||||||
Leprosy | ||||||||||||||||||||
Malaria | ||||||||||||||||||||
Schistosomiasis | ||||||||||||||||||||
Other Parasites |
References
- ↑ Saha TC, Singh H (November 2006). "Minimal change disease: a review". South. Med. J. 99 (11): 1264–70. doi:10.1097/01.smj.0000243183.87381.c2. PMID 17195422.
- ↑ Saleem MA, Kobayashi Y (2016). "Cell biology and genetics of minimal change disease". F1000Res. 5. doi:10.12688/f1000research.7300.1. PMC 4821284. PMID 27092244.
- ↑ Keskar V, Jamale TE, Kulkarni MJ, Kiggal Jagadish P, Fernandes G, Hase N (October 2013). "Minimal-change disease in adolescents and adults: epidemiology and therapeutic response". Clin Kidney J. 6 (5): 469–72. doi:10.1093/ckj/sft063. PMC 4438390. PMID 26064510.
- ↑ Chugh SS, Clement LC, Macé C (February 2012). "New insights into human minimal change disease: lessons from animal models". Am. J. Kidney Dis. 59 (2): 284–92. doi:10.1053/j.ajkd.2011.07.024. PMC 3253318. PMID 21974967.
- ↑ Rosenberg AZ, Kopp JB (March 2017). "Focal Segmental Glomerulosclerosis". Clin J Am Soc Nephrol. 12 (3): 502–517. doi:10.2215/CJN.05960616. PMC 5338705. PMID 28242845.
- ↑ Jefferson JA, Shankland SJ (September 2014). "The pathogenesis of focal segmental glomerulosclerosis". Adv Chronic Kidney Dis. 21 (5): 408–16. doi:10.1053/j.ackd.2014.05.009. PMC 4149756. PMID 25168829.
- ↑ Gephardt GN, Tubbs RR, Popowniak KL, McMahon JT (October 1986). "Focal and segmental glomerulosclerosis. Immunohistologic study of 20 renal biopsy specimens". Arch. Pathol. Lab. Med. 110 (10): 902–5. PMID 2429634.
- ↑ Lai WL, Yeh TH, Chen PM, Chan CK, Chiang WC, Chen YM, Wu KD, Tsai TJ (February 2015). "Membranous nephropathy: a review on the pathogenesis, diagnosis, and treatment". J. Formos. Med. Assoc. 114 (2): 102–11. doi:10.1016/j.jfma.2014.11.002. PMID 25558821.
- ↑ Wasserstein AG (April 1997). "Membranous glomerulonephritis". J. Am. Soc. Nephrol. 8 (4): 664–74. PMID 10495797.
- ↑ Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, Wyatt RJ, Scolari F, Mestecky J, Gharavi AG, Julian BA (October 2011). "The pathophysiology of IgA nephropathy". J. Am. Soc. Nephrol. 22 (10): 1795–803. doi:10.1681/ASN.2011050464. PMC 3892742. PMID 21949093.
- ↑ Wyatt RJ, Julian BA (June 2013). "IgA nephropathy". N. Engl. J. Med. 368 (25): 2402–14. doi:10.1056/NEJMra1206793. PMID 23782179.
- ↑ He S, Wu Z (November 2011). "Gene-based Higher Criticism methods for large-scale exonic single-nucleotide polymorphism data". BMC Proc. 5 Suppl 9: S65. doi:10.1186/1753-6561-5-S9-S65. PMC 3287904. PMID 22373436.
- ↑ Higgins RM, Goldsmith DJ, Connolly J, Scoble JE, Hendry BM, Ackrill P, Venning MC (January 1996). "Vasculitis and rapidly progressive glomerulonephritis in the elderly". Postgrad Med J. 72 (843): 41–4. PMC 2398323. PMID 8746284.
- ↑ Jennette JC (March 2003). "Rapidly progressive crescentic glomerulonephritis". Kidney Int. 63 (3): 1164–77. doi:10.1046/j.1523-1755.2003.00843.x. PMID 12631105.
- ↑ Bolton WK (November 1996). "Goodpasture's syndrome". Kidney Int. 50 (5): 1753–66. PMID 8914046.
- ↑ Mathew TH, Hobbs JB, Kalowski S, Sutherland PW, Kincaid-Smith P (February 1975). "Goodpasture's syndrome: normal renal diagnostic findings". Ann. Intern. Med. 82 (2): 215–8. PMID 1090223.
- ↑ Renaudineau Y, Le Meur Y (October 2008). "Renal involvement in Wegener's granulomatosis". Clin Rev Allergy Immunol. 35 (1–2): 22–9. doi:10.1007/s12016-007-8066-6. PMID 18172777.
- ↑ Weiss MA, Crissman JD (October 1984). "Renal biopsy findings in Wegener's granulomatosis: segmental necrotizing glomerulonephritis with glomerular thrombosis". Hum. Pathol. 15 (10): 943–56. PMID 6384024.
- ↑ Sinico RA, Di Toma L, Maggiore U, Tosoni C, Bottero P, Sabadini E, Giammarresi G, Tumiati B, Gregorini G, Pesci A, Monti S, Balestrieri G, Garini G, Vecchio F, Buzio C (May 2006). "Renal involvement in Churg-Strauss syndrome". Am. J. Kidney Dis. 47 (5): 770–9. doi:10.1053/j.ajkd.2006.01.026. PMID 16632015.
- ↑ Cartin-Ceba R, Keogh KA, Specks U, Sethi S, Fervenza FC (September 2011). "Rituximab for the treatment of Churg-Strauss syndrome with renal involvement". Nephrol. Dial. Transplant. 26 (9): 2865–71. doi:10.1093/ndt/gfq852. PMC 3218640. PMID 21325353.
- ↑ Chung SA, Seo P (August 2010). "Microscopic polyangiitis". Rheum. Dis. Clin. North Am. 36 (3): 545–58. doi:10.1016/j.rdc.2010.04.003. PMC 2917831. PMID 20688249.
- ↑ Pagnoux C (March 2008). "[Wegener's granulomatosis and microscopic polyangiitis]". Rev Prat (in French). 58 (5): 522–32. PMID 18524109.
- ↑ Alchi B, Jayne D (August 2010). "Membranoproliferative glomerulonephritis". Pediatr. Nephrol. 25 (8): 1409–18. doi:10.1007/s00467-009-1322-7. PMC 2887509. PMID 19908070.
- ↑ Davis AE, Schneeberger EE, Grupe WE, McCluskey RT (May 1978). "Membranoproliferative glomerulonephritis (MPGN type I) and dense deposit disease (DDD) in children". Clin. Nephrol. 9 (5): 184–93. PMID 657595.